Skip to main content

Table 3 Effect of alternative splice variant-expressing adenoviruses on joint inflammation and destruction

From: Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis

Alternative splice variant adenovirus Mice per group (n) Joints assessed (n) P value
    Clinical score Paw swelling Histological evaluation
Untreated 6 120 - - -
LacZ 6 164 0.4549 0.3759 0.3797
VEGFR1-541 5 53 <0.0001 <0.0001 0.0096
VEGFR2-712 5 44 <0.0001 0.1762 0.7340
VEGFR3-765 5 68 0.9366 0.2228 0.8148
Tie1-751 6 63 <0.0001 <0.0001 <0.001
Met-877 6 64 0.2924 0.6603 0.5038
c-Kit-413 6 55 0.0587 0.1501 0.1046
CSF1R-306 6 50 0.2448 0.5581 0.1510
PDGFRβ-336 6 41 0.8498 0.0632 0.8258
FGFR1-320 6 55 0.0044 0.0087 0.0568
RAGE-387 6 53 0.8543 0.1141 0.9799
  1. Following onset of arthritis, mice were treated with the alternative splice variant adenovirus indicated. Data presented as P values of mice treated with the indicated recombinant alternative splice variant adenoviruses as compared with untreated mice, and are expressed as the P value of clinical scores, paw swelling, and histological evaluation. For clinical scores and paw swelling, data were analyzed using two-way analysis of variance versus untreated mice. For histological evaluation, H & E and toluidine blue stained sections were scored for pannus formation, synovitis, and bone and cartilage erosion. Data were analyzed using the chi-square test for trend versus untreated mice.